-Role of immunotherapy (I) for advanced, pre-treated, non-squamous NSCLC (APNS-NSCLC): Preliminary data of a pooled analysis with network meta-analysis.
data pubblicazione: 23 ott 2018 ,Annals Of Oncology
-Abstract P3-11-05: Everolimus-exemestane (EE) vs palbociclib-fulvestrant (PF) or abemaciclib fulvestrant(AF) or everolimus-fulvestrant (EF) in the treatment of metastatic HR+, HER2- metastatic breast cancer and prior aromatase inhibitors treatment. An indirect comparison with network meta-analysis
data pubblicazione: 15 feb 2018, Cancer Research
-Immunotherapy (I) for advanced, pre-treated, non-squamous NSCLC (APNS-NSCLC): Preliminary data of a pooled analysis.
data pubblicazione: feb 2018, Journal of Clinical Oncology
